Charles River Stock Jumps 5.2% on Upgraded 2026 Outlook and 2030 Targets

Key Facts

1Charles River Laboratories shares rose 5.2% after reaffirming 2026 revenue and non-GAAP EPS outlook at the upper ends of previous ranges.

2The company unveiled 2030 strategic targets including accelerated organic growth, margin expansion, and a cost-savings plan.

In a move reflecting management's optimism regarding its long-term operational trajectory, Charles River Laboratories shares rose 5.2% following positive updates during its investor day. The company reaffirmed that its 2026 revenue and non-GAAP earnings per share are expected to land at the upper ends of previous guidance ranges. Additionally, the firm unveiled new strategic targets for 2030 focused on accelerating organic growth and expanding operating margins.

These projections are supported by the launch of the "Create the Future" cost-savings program, which boosted investor confidence in the company's ability to deliver sustainable, profitable growth. According to market data, CRL stock closed at $277.33 on September 23, 2026, with the session's trading range between a low of $276.64 and a high of $291.09.

Traders are now watching whether the stock can maintain support levels near the September 23, 2026 close of $277.33, given the absence of immediate major healthcare sector catalysts in the upcoming calendar. As markets stabilize following recent interest rate decisions in Japan and the UK, focus will shift to the execution of the announced cost-savings plan as a primary driver for the stock's performance.